Literature DB >> 1868362

The effects of THA on scopolamine and nucleus basalis lesion-induced EEG slowing.

P Riekkinen1, P Jäkälä, J Sirviö, E Koivisto, R Miettinen, P Riekkinen1.   

Abstract

The effectiveness of THA (an anticholinesterae) on scopolamine (0.4 mg/kg) and nucleus basalis (NB) lesion-induced change in neocortical spectral electroencephalography (EEG) were investigated. Scopolamine increased the amplitudes of all the spectral components in waking-immobility. In the movement-related EEG spectral values, only the alpha power was increased. THA 7.5 mg/kg, but not THA 3 mg/kg, could reverse scopolamine-induced amplitude change. NB lesioning increased delta and theta amplitudes, but decreased beta amplitude. Delta amplitude was increased during movement recordings in NB-lesioned rats. THA 7.5 mg/kg and pilocarpine 10 mg/kg, but not THA 3 mg/kg, could partially reverse the increase of delta and theta amplitudes induced by NB lesions. However, the beta power decrease could not be restored with cholinomimetics. This study demonstrates that quantitative EEG activity analysis may reflect the THA-induced restoration of the function of the cholinergic nucleus basalis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1868362     DOI: 10.1016/0361-9230(91)90107-u

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  3 in total

1.  Changes in electrocortical power and coherence in response to the selective cholinergic immunotoxin 192 IgG-saporin.

Authors:  D P Holschneider; J J Waite; A F Leuchter; N Y Walton; O U Scremin
Journal:  Exp Brain Res       Date:  1999-05       Impact factor: 1.972

2.  Effects of ZK 93426 on muscarinic and nicotinic antagonist or nucleus basalis lesioning-induced electrocortical slowing.

Authors:  P Riekkinen; M Riekkinen; J Sirviö; P Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 3.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.